Pfizer Inc.
PFE
Market Cap$163.88B
Close$
Earnings Call Q4 2023
January 30, 2024 - AI Summary
Pfizer reported full-year 2023 revenues of $58.5 billion, achieving 7% operational growth (excluding COVID products), in line with expectations.
The decline in revenue from COVID products significantly impacted the overall results, leading to a 41% year-over-year decrease in revenues.
Adjusted diluted earnings per share for 2023 were $1.84, down 72% compared to the previous year, primarily due to lower sales of Comirnaty and Paxlovid.
Exclusive for Stockcircle Pro members
Sign up
$62.20
115.1% upside
Current Fair Value
115.1% upsideUndervalued by 115.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $163.88 Billion |
|---|---|
| Enterprise Value | $221.49 Billion |
| Dividend Yield | $1.6243 (5.62%) |
| Earnings per Share | $-0.05 |
| Beta | 0.37 |
| Outstanding Shares | 5,666,592,898 |
| Avg 30 Day Volume | 44,770,202 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -528.64 |
|---|---|
| PEG | 1206.85 |
| Price to Sales | 3.21 |
| Price to Book Ratio | 1.81 |
| Enterprise Value to Revenue | 4.02 |
| Enterprise Value to EBIT | 89.27 |
| Enterprise Value to Net Income | -715 |
| Total Debt to Enterprise | 0.31 |
| Debt to Equity | 0.75 |
Revenue Sources
No data
ESG Score
No data
About Pfizer Inc.
CEO: Albert Bourla